Wuxi-Based Roomey Unveils State-of-the-Art IVD Production Facility in High-tech Zone

Wuxi, China – Roomey, a leading innovator in in vitro diagnostics (IVD), has officially launched its cutting-edge production facility in Wuxi’s High-tech Zone. The new facility is poised to enhance the company’s manufacturing capabilities, particularly for its high-performance CRP & SAA Kits for Mindray Hematology Analyzers, reinforcing its commitment to precision diagnostics and global healthcare advancements.

Expanding Diagnostic Excellence

The newly inaugurated facility spans over 10,000 square meters and integrates advanced automation, stringent quality control systems, and sustainable production practices. Designed to meet international standards, the facility will significantly boost Roomey’s output of IVD reagents, with a strong focus on CRP (C-reactive protein) and SAA (serum amyloid A) kits tailored for Mindray’s hematology analyzers. These kits are critical for diagnosing and monitoring inflammatory conditions, infections, and autoimmune diseases.

Meeting Global Demand with Precision

Roomey’s CRP & SAA Kits are engineered to deliver high accuracy, stability, and compatibility with Mindray’s widely used hematology systems. The expansion into Wuxi’s High-tech Zone enables Roomey to scale production while maintaining rigorous quality benchmarks, ensuring timely deliveries to markets across Asia, Europe, and North America.

• Enhanced Sensitivity: Early detection of low-grade inflammation.
• Rapid Turnaround: Streamlined workflows for clinical laboratories.
• Cost-Efficiency: Optimized reagent formulations reduce operational costs.

Driving Innovation in IVD

Dr. Li Wei, Roomey’s Chief Technology Officer, emphasized the facility’s role in advancing diagnostic solutions: “This facility represents a leap forward in IVD manufacturing. By leveraging automation and AI-driven quality assurance, we’re not only increasing capacity but also pioneering next-gen assays for unmet clinical needs.”

The company’s R&D team is concurrently developing multi-marker panels to complement its CRP & SAA offerings, aiming to provide clinicians with comprehensive tools for disease stratification and treatment monitoring.

Commitment to Sustainability

Aligned with global environmental goals, the Wuxi facility incorporates energy-efficient processes and waste-reduction protocols. Roomey has also partnered with local universities to foster talent in biomedical engineering, further cementing its presence in Wuxi’s thriving biotech ecosystem.

Looking Ahead

With this expansion, Roomey is set to strengthen its position as a trusted IVD partner for hospitals and laboratories worldwide. The company plans to introduce five new reagent lines by 2025, targeting emerging diagnostic challenges in cardiology and oncology.

For more information on Roomey’s CRP & SAA Kits for Mindray Hematology Analyzers, visit their official website or contact their global sales team.